FEDERAL Health Minister Mark Butler has announced the PBS listing of Ocrevus SC (ocrelizumab, Roche), the world's first 10-minute, six-monthly injection to treat multiple sclerosis.
The quick and convenient subcutaneous injection reduces inflammation and attacks on the nervous system of patients living with relapsing-remitting MS, a debilitating form of the disease affecting more than 32,000 Australians.
Known medically as a high-efficacy disease-modifying therapy, Ocrevus works by targeting and depleting specific immune cells, known as B cells, which can mistakenly attack the myelin sheath that protects the body's nerves.
Without the PBS subsidy, the drug cost $16,500 per injection.and MS experts and advocates have welcomed the funding.
"Relapsing-remitting multiple sclerosis is an unpredictable disease," said Associate Professor John Parratt, a neurologist from Sydney's Royal North Shore Hospital.
"Without effective treatment, it can rob people of their movement, energy, sight and independence, and the availability of a new treatment option is extremely welcome."
MS is also on the rise in Australia, with new data released by this week reporting a 77% increase in the number of people living with the disease since 2010.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Dec 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Dec 25
